Overview

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Status:
Not yet recruiting
Trial end date:
2025-04-04
Target enrollment:
Participant gender:
Summary
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks. In addition to taking the medicine, participants will have talks with study staff about: - Healthy food choices - How to be more physically active - What participants can do to lose weight This study will last for about 1 year.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S